ANDA 207170, held by Everest Lifesciences. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 207170 (Tizanidine Hydrochloride), held by Everest Lifesciences, was first approved by FDA on Jan 26, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 26, 2017 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · tablet;oral | Tizanidine Hydrochloride | Discontinued |
| Tizanidine HydrochlorideEQ 4MG BASE · tablet;oral | Tizanidine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters